MOORESTOWN, N.J., Oct. 04, 2016 -- Tabula Rasa HealthCare, Inc. (NASDAQ:TRHC), a leader in providing patient-specific, data-driven technology and solutions that enable healthcare organizations to optimize medication regimens to improve patient outcomes, reduce hospitalizations, lower healthcare costs and manage risk, today announced the closing of its initial public offering of 4,945,000 shares of common stock at an initial public offering price of $12.00 per share, which includes the exercise in full by the underwriters of their option to purchase up to 645,000 additional shares of common stock. All of the shares in the offering were offered by Tabula Rasa. Tabula Rasa’s common stock is listed on the NASDAQ Global Market under the ticker symbol "TRHC." Tabula Rasa estimates net proceeds from the offering to be approximately $51.6 million, after deducting underwriting discounts and commissions and estimated offering expenses.
Wells Fargo Securities and UBS Investment Bank acted as joint-book running managers for the offering. Piper Jaffray also acted as a book-runner and Baird and Stifel acted as co-managers for the offering.
A registration statement relating to these securities has been filed with the Securities and Exchange Commission and was declared effective on September 28, 2016. The offering will be made only by means of a written prospectus forming part of the effective registration statement. A copy of the final prospectus relating to this offering, when available, may be obtained for free by visiting EDGAR on the SEC's website at www.sec.gov, or alternatively, from: Wells Fargo Securities, LLC by mailing: Attention: Equity Syndicate Department, 375 Park Avenue, New York, NY 10152, by email: [email protected] or by Telephone: (800) 326-5897, or from UBS Securities LLC by mailing: Attention: Prospectus Department, 1285 Avenue of the Americas, New York, NY 10019 or by Telephone: (888) 827-7275.
This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
About Tabula Rasa HealthCare
Tabula Rasa HealthCare (TRHC) is a leader in providing patient-specific, data-driven technology and solutions that enable healthcare organizations to optimize medication regimens to improve patient outcomes, reduce hospitalizations, lower healthcare costs and manage risk. Medication risk management is TRHC’s lead offering, and its cloud-based software applications provide solutions for a range of payers, providers and other healthcare organizations. For more information, please visit: www.tabularasahealthcare.com.
Contact Bob East or Asher Dewhurst Westwicke Partners 443-213-0500 [email protected]


First Western Ship Transits Strait of Hormuz Since Iran War Began
Norma Group Posts Revenue Decline in 2025, Eyes Modest Recovery in 2026
MATCH Act Targets ASML and Chinese Chipmakers in New U.S. Export Crackdown
Tesla Q1 2026 Deliveries Miss Estimates as AI Strategy Takes Center Stage
Microsoft Eyes $7B Texas Energy Deal to Power AI Data Centers
Microsoft's $10 Billion Japan Investment: AI Infrastructure and Data Sovereignty Push
Trump Administration Plans 100% Tariffs on Pharmaceutical Imports
Samsung Electronics Eyes Record Q1 Profit Amid AI-Driven Chip Boom
UAE's Largest Natural Gas Facility Suspended After Attack-Triggered Fire
RBC Capital: European Medtech Firms Show Minimal Middle East and Energy Risk Exposure
LG Electronics Posts Record Q1 Revenue Amid Strong Demand and Cost Improvements
TSMC Japan's Second Fab to Produce 3nm Chips by 2028
Annie Altman Amends Sexual Abuse Lawsuit Against OpenAI CEO Sam Altman
Fonterra Admits Anchor Butter "Grass-Fed" Label Misled Consumers After Greenpeace Lawsuit
UPS and Teamsters Reach Agreement to Limit Driver Severance Program
Nike Beats Q3 Estimates but China Weakness and Margin Pressure Weigh on Outlook
SoftwareONE Posts 22.5% Revenue Surge in 2025 on Crayon Acquisition 



